Myriad Genetics Inc (MYGN) — Analysis Summary
Myriad Genetics Inc (MYGN) has a market cap of $302.25M with year-over-year revenue growth of -1.6%. Net margin stands at -44.4%. The stock trades at a P/E ratio of -2.7.
Key Takeaways
- Revenue changed -1.6% year-over-year
- Net margin of -44.4%
- P/E ratio of -2.7
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, MYGN posted revenue growth of -1.6% and trades at a P/E of -2.7.
Myriad Genetics Inc (MYGN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -6.0x — earnings do not cover interest payments
Operating margin at -12.2% — material operating losses
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
2,700
Headquarters
SALT LAKE CITY, UT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.